Pengaruh Polimorfisme P2Y12 Pada Penggunaan Antiplatelet Terhadap Kejadian Stroke Berulang

oktaviarika dewi hermawatiningsih; Rahmawati Raising

doi:10.30591/pjif.v12i1.4414

Pengaruh Polimorfisme P2Y12 Pada Penggunaan Antiplatelet Terhadap Kejadian Stroke Berulang

oktaviarika dewi hermawatiningsih, Rahmawati Raising

Abstract

Stroke merupakan keadaan defisit neurologik secara fokal dan global. Salah satu pengobatan yang digunakan adalah antiplatelet seperti clopidogrel yang dapat menghambat pembentukan trombus yang bisa menurunkan angka kematian. Dalam perkembangan pengobatan, terdapat variasi respon pasien terhadap terapi clopidogrel. Variasi respon tersebut seperti polimorfisme reseptor P2Y12 yang berdampak pada farmakokinetik dan farmakodinamil dari clopidogrel. Tujuan dari penelitian ini adalah untuk menyetahui pengaruh kejadian polimorfisme reseptor P2Y12 terhadap kejadian stroke berulang. Metode yang digunakan dalam peneltian ini adalah metode Polymerase Chain Reaction (PCR) yaitu dengan cara pemeriksaan polimorfisme genetik P2Y12 dan dilakukan pemantauan setiap bulan untuk mengetahui kejadian stroke berulang. Hasil yang diperoleh dari penelitian ini adalah dari 20 sampel diperoleh jenis polimorfime P2Y12 homozygot (wild type), untuk kejadian stroke berulang diperoleh 4 sampel yang mengalami kejadian stroke berulang, dan analisis pengaruh polimorfisme P2Y12 terhadap kejadian stroke berulang diperoleh nilai signifikansi >0,05, sehingga dalam penelitian ini dapat disimpulkan bahwa tidak terdapat pengaruh antara polimorfisme P2Y12 terhadap kejadian stroke berulang.

Full Text:

References

ALGAS ORGANICS InterLab (2019) ‘Certificate of Analysis Certificate of Analysis’, Sigma-Aldrich, (281), p. 1. Available at: https://cellgenix.com/products/gmp- scgm/.

ALGAS ORGANICS InterLab (2019) ‘Certificate of Analysis Certificate of Analysis’, Sigma-Aldrich, (281), p. 1. Available at: https://cellgenix.com/products/gmp-scgm/.

Bierend, A. et al. (2007) ‘antiplatelet effects of aspirin in patients with coronary artery disease’. Available at: https://doi.org/10.1111/j.1365-2125.2007.03044.x.

Cuisset, T. et al. (2007) ‘Role of the T744C polymorphism of the P2Y12 gene on platelet response to a 600-mg loading dose of clopidogrel in 597 patients with non-ST-segment elevation acute coronary syndrome’, Thrombosis Research, 120(6), pp. 893–899. Available at: https://doi.org/10.1016/j.thromres.2007.01.012.

Frelinger, A.L. et al. (2013) ‘Clopidogrel pharmacokinetics and pharmacodynamics vary widely despite exclusion or control of polymorphisms (CYP2C19, ABCB1, PON1), noncompliance, diet, smoking, co-medications (Including Proton Pump Inhibitors), and pre-existent variability in platelet f’, Journal of the American College of Cardiology, 61(8), pp. 872–879. Available at: https://doi.org/10.1016/j.jacc.2012.11.040.

Hetherington, S.L. et al. (2005) ‘Dimorphism in the P2Y1 ADP Receptor Gene Is Associated With Increased Platelet Activation Response to ADP’. Available at: https://doi.org/10.1161/01.ATV.0000148708.44691.27.

Kannel, B. (1976) ‘EPIDEMIOLOGY A General Cardiovascular Risk Profile : The Framingham Study’, 36(July), pp. 46–51.

Kemenkes RI (2018) ‘Stroke Dont Be The One’, p. 10.

Li, M. et al. (2017) ‘Associations between P2RY12 gene polymorphisms and risks of clopidogrel resistance and adverse cardiovascular events after PCI in patients with acute coronary syndrome’, Medicine (United States), 96(14). Available at: https://doi.org/10.1097/MD.0000000000006553.

Mǎrginean, A. et al. (2017) ‘The Impact of CYP2C19 Loss-of-Function Polymorphisms, Clinical, and Demographic Variables on Platelet Response to Clopidogrel Evaluated Using Impedance Aggregometry’, Clinical and Applied Thrombosis/Hemostasis, 23(3), pp. 255–265. Available at: https://doi.org/10.1177/1076029616629211.

Priyadharsini, R. et al. (2017) ‘Frequency of single nucleotide platelet receptor gene polymorphism ( P2Y12-i744T > C ) in coronary artery disease patients among Tamilian population’, pp. 3–8. Available at: https://doi.org/10.1007/s12687-017-0293-9.

Promega (2017) ‘Technical Manual Wizard® Genomic DNA Purification Kit’, Promega Corporation, pp. 1–18. Available at: https://worldwide.promega.com/resources/protocols/technical-manuals/0/wizard-genomic-dna-purification-kit-protocol/.

Riskesdas Jatim (2018) Laporan Provinsi Jawa Timur RISKESDAS 2018, Kementerian Kesehatan RI.

Saraf, S., Bensalha, I. and Gorog, D.A. (2009) ‘Antiplatelet resistance - Does it exist and how to measure it?’, Clinical Medicine: Cardiology, 2009(3), pp. 77–91. Available at: https://doi.org/10.4137/cmc.s2159.

Scott, S.A. et al. (2013) ‘Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C19 Genotype and Clopidogrel Therapy : 2013 Update’, 94(3), pp. 317–323. Available at: https://doi.org/10.1038/clpt.2013.105.

T.A. Brown (2010) Gene Cloning & DNA Analysis. Sixth Edit. Manchester.

Yi, X. et al. (2017) ‘Interaction among CYP 2C8, GPIIIa and P2Y12 variants increase susceptibility to ischemic stroke in chinese population’, Oncotarget, 8(41), pp. 70811–70820. Available at: https://doi.org/10.18632/oncotarget.19991.

Ziegler, S. et al. (2005) ‘Association of a Functional Polymorphism in the Clopidogrel Target Receptor Gene , P2Y12 , and the Risk for Ischemic Cerebrovascular Events in Patients With Peripheral Artery Disease’. Available at: https://doi.org/10.1161/01.STR.0000169922.79281.a5.

DOI: https://doi.org/10.30591/pjif.v12i1.4414